Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions
Open accessAbstract
Liposomal amphotericin B (AmBisome(®); LAmB) is a unique lipid formulation of amphotericin B. LAmB is a standard of care for a wide range of medically important opportunistic fungal pathogens. LAmB has a significantly improved toxicity profile compared with conventional amphotericin B deoxycholate (DAmB). Despite nearly 20 years of clinical use, the pharmacokinetics and pharmacodynamics of this agent, which differ considerably from DAmB, remain relatively poorly understood and underutilized in the clinical setting. The molecular pharmacology, preclinical and clinical pharmacokinetics, and clinical experience with LAmB for the most commonly encountered fungal pathogens are reviewed. In vitro, experimental animal models and human clinical trial data are summarized, and novel routes of administration and dosing schedules are discussed. LAmB is a formulation that results in reduced toxicity as compared with DAmB while retaining the antifungal effect of the active agent. Its long terminal half-life and retention in tissues suggest that single or intermittent dosing regimens are feasible, and these should be actively investigated in both preclinical models and in clinical trials. Significant gaps remain in knowledge of pharmacokinetics and pharmacodynamics in special populations such as neonates and children, pregnant women and obese patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Liposome bilayer-coated amphotericin B (LAmB) reduces toxicity while retaining antifungal activity, mitigating the dosage limitation of conventional amphotericin B deoxycholate (DAmB).
“Liposome bilayer-coated amphotericin B (LAmB) has been developed to reduce toxicity while retaining antifungal activity, mitigating the dosage limitation of conventional amphotericin B deoxycholate (DAmB)9.”
From Treatment strategies for cryptococcal infection: challenges, advances and future outlook (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664 · see citing works
Szer, J. (1999) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,376 · see citing works
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,685 · see citing works
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660 · see citing works
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205 · see citing works
Papahadjopoulos, D., Jacobson, K., Nir, S., & Isac, I. (1973) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(73)90314-3 · Cited by 998 · see citing works
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979 · see citing works
Walsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R., Dmoszyńska, A., Cornely, O. A., Bourque, M. R., Lupinacci, R. J., Sable, C. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040446 · Cited by 905 · see citing works
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807 · see citing works
Cornely, O. A., Maertens, J. A., Bresnik, M., Ebrahimi, R., Ullmann, A. J., Bouza, E., Heußel, C. P., Lortholary, O., Rieger, C. T., Boehme, A., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/514341 · Cited by 745 · see citing works
Kuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60605-9 · Cited by 692 · see citing works
Combination Antifungal Therapy for Cryptococcal Meningitis
Day, J., Chau, T. T., Wolbers, M., Mai, P. P., Dung, N. T., Mai, N. H., Phu, N. H., Nghia, H. D. T., Phong, N. D., Cao, Q. T., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1110404 · Cited by 542 · see citing works
Wingard, J. R., White, M. H., Anaissie, E. J., Raffalli, J. T., Goodman, J., Arrieta, A. C., & L Amph/ABLC Collaborative Study Group (2000) · Clinical Infectious Diseases · doi:10.1086/317451 · Cited by 524 · see citing works
Prentice, H. G., Hann, I. M., Herbrecht, R., Aoun, M., Kvaløy, S., Catovsky, D., Pinkerton, R., Schey, S., Jacobs, F., Oakhill, A., et al. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2473063.x · Cited by 437 · see citing works
Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Sundar, S., Chakravarty, J., Agarwal, D., Rai, M., & Murray, H. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0903627 · Cited by 436 · see citing works
Tissue Penetration of Antifungal Agents
Felton, T., Troke, P. F., & Hope, W. W. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-13 · Cited by 426 · see citing works
Self-citationGroll, A. H., Giri, N., Petraitis, V., Petraitienė, R., Candelario, M., Bacher, J., Piscitelli, S. C., & Walsh, T. J. (2000) · The Journal of Infectious Diseases · doi:10.1086/315643 · Cited by 373 · see citing works
Johnson, P. C., Wheat, L. J., Cloud, G. A., Goldman, M., Lancaster, D., Bamberger, D. M., Powderly, W. G., Hafner, R., Kauffman, C. A., & Dismukes, W. E. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-2-200207160-00008 · Cited by 366 · see citing works
Tissue concentrations: do we ever learn?
Mouton, J. W., Theuretzbacher, U., Craig, W. A., Tulkens, P. M., Derendorf, H., & Cars, O. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm476 · Cited by 352 · see citing works
Bern, C., Adler‐Moore, J., Berenguer, J., Boelaert, M., den Boer, M., Davidson, R. N., Figueras, C., Gradoni, L., Kafetzis, D. A., Ritmeijer, K., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/507530 · Cited by 342 · see citing works
Sundar, S., Sinha, P. K., Rai, M., Verma, D. K., Kumar, N., Alam, S., Chakravarty, J., Vaillant, M., Verma, N., Pandey, K., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62050-8 · Cited by 339 · see citing works
AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience
Adler‐Moore, J., & Proffitt, R. T. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.suppl_1.21 · Cited by 339 · see citing works
Bekersky, I., Fielding, R. M., Dressler, D. E., Lee, J. W., Buell, D. N., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.828-833.2002 · Cited by 320 · see citing works
Leenders, A. C. A. P., Daenen, S. M. G. J., Jansen, R. L. H., Hop, W. C. J., Löwenberg, B., Wijermans, P., Cornelissen, J. J., Herbrecht, R., van der Lelie, H., Hoogsteden, H. C., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00944.x · Cited by 317 · see citing works
Spellberg, B., Ibrahim, A. S., Chin-Hong, P. V., Kontoyiannis, D. P., Morris, M. I., Perfect, J. R., Fredricks, D., & Brass, E. P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr375 · Cited by 308 · see citing works
Leenders, A. C. A. P., Reiss, P., Portegies, P., Clezy, K. R., Hop, W. C. J., Hoy, J., Borleffs, J. C. C., Allworth, T., Kauffmann, R. H., Jones, P., et al. (1997) · AIDS · doi:10.1097/00002030-199712000-00010 · Cited by 287 · see citing works
Rijnders, B. J. A., Cornelissen, J. J., Slobbe, L., Becker, M. J., Doorduijn, J. K., Hop, W. C. J., Ruijgrok, E. J., Löwenberg, B., Vulto, A. G., Lugtenburg, P. J., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/586739 · Cited by 284 · see citing works
Adler‐Moore, J., & Proffitt, R. T. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150729 · Cited by 252 · see citing works
Ellis, M. E., Spence, D. J., de Pauw, B., Meunier, F., Marinus, A., Collette, L., Sylvester, R. J., Meis, J. F. G. M., Boogaerts, M. A., Selleslag, D., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/515033 · Cited by 249 · see citing works
Ramage, G., VandeWalle, K., Bachmann, S. P., Wickes, B. L., & Lopez-Ribot, J. L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3634-3636.2002 · Cited by 238 · see citing works
Bekersky, I., Fielding, R. M., Dressler, D. E., Lee, J. W., Buell, D. N., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.834-840.2002 · Cited by 237 · see citing works
Sau, K., Mambula, S. S., Latz, E., Henneke, P., Golenbock, D. T., & Levitz, S. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306137200 · Cited by 216 · see citing works
Micafungin Versus Liposomal Amphotericin B for Pediatric Patients With Invasive Candidiasis
Queiroz‐Telles, F., Berezin, E. N., Leverger, G., Freire, A., van der Vyver, A., Chotpitayasunondh, T., Konja, J., Diekmann-Berndt, H., Koblinger, S., Groll, A. H., et al. (2008) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31817275e6 · Cited by 210 · see citing works
Walsh, T. J., Yeldandi, V. V., McEvoy, M., Gonzalez, C. E., Chanock, S. J., Freifeld, A. G., Seibel, N., Whitcomb, P. O., Jarosinski, P. F., Boswell, G. W., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2391 · Cited by 189 · see citing works
Francis, P., Lee, J. W., Hoffman, A. G. D., Peter, J., Francesconi, A., Bacher, J., Shelhamer, J. H., Pizzo, P. A., & Walsh, T. J. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.2.356 · Cited by 185 · see citing works
Rabbit Model of Candida albicans Biofilm Infection: Liposomal Amphotericin B Antifungal Lock Therapy
Schinabeck, M. K., Long, L. A., Hossain, M. A., Chandra, J., Mukherjee, P. K., Mohamed, S., & Ghannoum, M. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1727-1732.2004 · Cited by 181 · see citing works
Hamill, R. J., Sobel, J. D., El-Sadr, W. M., Johnson, P. C., Graybill, J. R., Javaly, K., & Barker, D. E. (2010) · Clinical Infectious Diseases · doi:10.1086/653606 · Cited by 173 · see citing works
Kelsey, S. M., Goldman, J. M., McCann, S. R., Newland, A. C., Scarffe, J. H., Oppenheim, B. A., & Mufti, G. J. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701543 · Cited by 172 · see citing works
Szebeni, J., Baranyi, L., Sávay, S., Bodo, M., Morse, D. S., Bašta, M., Stahl, G. L., Bünger, R., & Alving, C. R. (2000) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2000.279.3.h1319 · Cited by 172 · see citing works
Antimicrobial Dosing in Obese Patients
Wurtz, R. M., Itokazu, G. S., & Rodvold, K. A. (1997) · Clinical Infectious Diseases · doi:10.1086/514505 · Cited by 157 · see citing works
The Formation of Amphotericin B Ion Channels in Lipid Bilayers
Fujii, G., Chang, J.-E., Coley, T. R., & Steere, B. A. (1997) · Biochemistry · doi:10.1021/bi962894z · Cited by 148 · see citing works
Lee, J. W., Amantea, M., Francis, P. A., Navarro, E. E., Bacher, J. D., Pizzo, P. A., & Walsh, T. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.713 · Cited by 134 · see citing works
Sundar, S., Jha, T. K., Thakur, C. P., Mishra, M., Singh, V. P., & Buffels, R. (2003) · Clinical Infectious Diseases · doi:10.1086/377542 · Cited by 134 · see citing works
Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature
Pagliano, P., Carannante, N., Rossi, M., GRAMICCIA, M., Gradoni, L., Faella, F. S., & Gaeta, G. B. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh538 · Cited by 133 · see citing works
Gregoriadis, G. C. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.39 · Cited by 129 · see citing works
Amphotericin B lipid preparations: what are the differences?
Adler‐Moore, J., & Proffitt, R. T. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01979.x · Cited by 128 · see citing works
Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS
Coker, R. J., Viviani, M. A., Gazzard, B., Pont, B. D., Pohle, H. D., Murphy, S. M., Atouguia, J., Champalimaud, J. L., & Harris, J. R. W. (1993) · AIDS · doi:10.1097/00002030-199306000-00011 · Cited by 119 · see citing works
Vogelsinger, H. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl141 · Cited by 118 · see citing works
Penack, O., Schwartz, S., Martus, P., Reinwald, M., Schmidt‐Hieber, M., Thiel, E., & Blau, I. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl128 · Cited by 116 · see citing works
Equilibrium binding of amphotericin B and its methyl ester and borate complex to sterols
Readio, J. D., & Bittman, R. (1982) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(82)90103-1 · Cited by 115 · see citing works
Singh, N., Paterson, D. L., Gayowski, T., Wagener, M. M., & Marino, I. R. (2001) · Transplantation · doi:10.1097/00007890-200104150-00016 · Cited by 112 · see citing works
Roden, M. M., Nelson, L. D., Knudsen, T. A., Jarosinski, P. F., Starling, J. M., Shiflett, S. E., Calis, K. A., DeChristoforo, R., Donowitz, G. R., Buell, D. N., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374553 · Cited by 109 · see citing works
Fortün, J. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg450 · Cited by 107 · see citing works
Wheat, L. J., Cloud, G. A., Johnson, P. C., Connolly, P., Goldman, M., LeMonte, A. M., Fuller, D., Davis, T. E., & Hafner, R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.8.2354-2357.2001 · Cited by 107 · see citing works
Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients
Heinemann, V., Bosse, D., Jehn, U., Kähny, B., Wachholz, K., Debus, A., Scholz, P., Kolb, H. J., & Wilmanns, W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1275 · Cited by 107 · see citing works
AmBisome targeting to fungal infections.
Adler‐Moore, J. (1994) · PubMed · Cited by 107 · see citing works
Monforte, V., Ussetti, P., López, R. M., Gavaldà, J., Bravo, C., de Pablo, A., Pou, L., Pahissa, A., Morell, F., & Román, A. (2009) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.11.004 · Cited by 106 · see citing works
Clemons, K. V., & Stevens, D. A. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.4.899 · Cited by 105 · see citing works
Hong, Y., Shaw, P. J., Nath, C. E., Yadav, S. P., Stephen, K. R., Earl, J. W., & McLachlan, A. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.935-942.2006 · Cited by 102 · see citing works
Khalil, E. A. G., Weldegebreal, T., Younis, B. M., Omollo, R., Musa, A. M., Hailu, W., Abuzaid, A. A., Dorlo, T. P. C., Hurissa, Z., Yifru, S., et al. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002613 · Cited by 101 · see citing works
Monforte, V., Ussetti, P., Gavaldà, J., Bravo, C., Laporta, R., Len, Ó., García-Gallo, C. L., Tenorio, L., Solé, J., & Román, A. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2009.11.603 · Cited by 100 · see citing works
Does Lipid Emulsion Reduce Amphotericin B Nephrotoxicity? A Systematic Review and Meta-analysis
Mistro, S., Maciel, I. D. M., de Menezes, R. G., Maia, Z. P. G., Schooley, R. T., & Badaró, R. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis290 · Cited by 92 · see citing works
Polso, A. K., Lassiter, J., & Nagel, J. L. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12200 · Cited by 85 · see citing works
Clinical Pharmacokinetics of Systemically Administered Antimycotics
Bellmann, R. (2007) · Current Clinical Pharmacology · doi:10.2174/157488407779422311 · Cited by 84 · see citing works
Lewis, R. E., Albert, N. D., Liao, G., Hou, J., Prince, R. A., & Kontoyiannis, D. P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01222-09 · Cited by 82 · see citing works
Wasan, K. M., Morton, R. E., Rosenblum, M. G., & Lopez‐Berestein, G. (1994) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600830716 · Cited by 82 · see citing works
Adler‐Moore, J., Chiang, S.-M., Satorius, A., Guerra, D., McAndrews, B., McManus, E. J., & Proffitt, R. T. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.63 · Cited by 81 · see citing works
Gershkovich, P., Wasan, E. K., Lin, M., Sivak, O., Leon, C. G., Clement, J. G., & Wasan, K. M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp140 · Cited by 81 · see citing works
Combination Antifungal Therapy for Cryptococcal Meningitis
Loyse, A., Bicanic, T. A., & Jarvis, J. N. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1305981 · Cited by 78 · see citing works
Self-citationCompartmentalized Intrapulmonary Pharmacokinetics of Amphotericin B and Its Lipid Formulations
Groll, A. H., Lyman, C. A., Petraitis, V., Petraitienė, R., Armstrong, D., Mickiene, D., Alfaro, R. M., Schaufele, R. L., Sein, T., Bacher, J. D., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00241-06 · Cited by 77 · see citing works
Olson, J. A., Adler‐Moore, J., Smith, P. J., & Proffitt, R. T. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.4895-4902.2005 · Cited by 75 · see citing works
Olson, J. A., Adler‐Moore, J., Schwartz, J., Jensen, G. M., & Proffitt, R. T. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00315-06 · Cited by 72 · see citing works
Boswell, G. W., Bekersky, I., Buell, D. N., Hiles, R., & Walsh, T. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.263 · Cited by 72 · see citing works
van Etten, E. W. M., Groot, C. V. D. H.-D., & Bakker‐Woudenberg, I. A. J. M. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/32.5.723 · Cited by 71 · see citing works
Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B
Loo, A. S., Muhsin, S. A., & Walsh, T. J. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.827168 · Cited by 70 · see citing works
Cordonnier, C., Mohty, M., Faucher, C., Pautas, C., Robin, M., Vey, N., Monchecourt, F., Mahi, L., & Ribaud, P. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.10.001 · Cited by 70 · see citing works
The Hepatotoxicity of Antifungal Medications in Bone Marrow Transplant Recipients
Fischer, M. A., Winkelmayer, W. C., Rubin, R. H., & Avorn, J. (2005) · Clinical Infectious Diseases · doi:10.1086/431586 · Cited by 67 · see citing works
Safety and Toxicokinetics of Intravenous Liposomal Amphotericin B (AmBisome ®) in Beagle Dogs
Bekersky, I., Boswell, G. W., Hiles, R., Fielding, R. M., Buell, D. N., & Walsh, T. J. (1999) · Pharmaceutical Research · doi:10.1023/a:1018997730462 · Cited by 64 · see citing works
Comparison of Lipid Amphotericin B Preparations in Treating Murine Zygomycosis
Ibrahim, A. S., Gebremariam, T., Husseiny, M. I., Stevens, D. A., Fu, Y., Edwards, J. E., & Spellberg, B. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01488-07 · Cited by 64 · see citing works
van Etten, E. W. M., ten Kate, M. T., Stearne, L. E. T., & Bakker‐Woudenberg, I. A. J. M. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.9.1954 · Cited by 64 · see citing works
Bekersky, I., Boswell, G. W., Hiles, R., Fielding, R. M., Buell, D. N., & Walsh, T. J. (2000) · Pharmaceutical Research · doi:10.1023/a:1007605024942 · Cited by 63 · see citing works
Wasan, E. K., Gershkovich, P., Zhao, J., Zhu, X., Werbovetz, K. A., Tidwell, R. R., Clement, J. G., Thornton, S. J., & Wasan, K. M. (2010) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000913 · Cited by 63 · see citing works
O’Connor, L., Livermore, J., Sharp, J., Goodwin, J., Gregson, L., Howard, S. J., Felton, T., Schwartz, J. A., Neely, M. N., Harrison, T. S., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit164 · Cited by 60 · see citing works
Self-citationSun, H., Alexander, B. D., Lortholary, O., Dromer, F., Forrest, G. N., Lyon, G. M., Somani, J., Gupta, K. L., Busto, R. D., Pruett, T. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/647948 · Cited by 60 · see citing works
Wade, R. L., Chaudhari, P., Natoli, J. L., Taylor, R. J., Nathanson, B. H., & Horn, D. L. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.04.001 · Cited by 59 · see citing works
Smith, P. J., Olson, J. A., Constable, D., Schwartz, J., Proffitt, R. T., & Adler‐Moore, J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm077 · Cited by 58 · see citing works
Treatment of Central Venous Catheter Fungal Infection Using Liposomal Amphotericin-B Lock Therapy
Buckler, B. S., Sams, R. N., Goei, V. L., Krishnan, K. R., Bemis, M. J., Parker, D. P., & Murray, D. L. (2008) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318170b68b · Cited by 56 · see citing works
Kolve, H., Ahlke, E., Fegeler, W., Ritter, J., Jürgens, H., & Groll, A. H. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp196 · Cited by 56 · see citing works
An Evaluation of Hepatotoxicity and Nephrotoxicity of Liposomal Amphotericin B (L-AMB)
Patel, G. P., Crank, C. W., & Leikin, J. B. (2010) · Journal of Medical Toxicology · doi:10.1007/s13181-010-0120-8 · Cited by 55 · see citing works
Cheikh, J. E., Faucher, C., Fürst, S., Duran, S., Berger, P., Vey, N., Stoppa, A. M., Bouabdallah, R., Gastaut, J. A., Viens, P., et al. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705592 · Cited by 55 · see citing works
Lestner, J. M., Howard, S. J., Goodwin, J., Gregson, L., Majithiya, J. B., Walsh, T. J., Jensen, G. M., & Hope, W. W. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01586-09 · Cited by 54 · see citing works
Self-citationGangneux, J., Sulahian, A., GARIN, Y. J. F., Farinotti, R., & Derouin, F. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.5.1214 · Cited by 52 · see citing works
García, A. C., Adler‐Moore, J., & Proffitt, R. T. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2327-2332.2000 · Cited by 51 · see citing works
Würthwein, G., Young, C., Lanvers‐Kaminsky, C., Hempel, G., Trame, M. N., Schwerdtfeger, R., Ostermann, H., Heinz, W., Cornely, O. A., Kolve, H., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00265-11 · Cited by 47 · see citing works
Takemoto, K., Yamamoto, Y., Ueda, Y., Sumita, Y., Yoshida, K., & Niki, Y. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl005 · Cited by 44 · see citing works
Clemons, K. V., & Stevens, D. A. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/32.3.465 · Cited by 42 · see citing works
Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema.
Purcell, I. F., & Corris, P. A. (1995) · Thorax · doi:10.1136/thx.50.12.1321 · Cited by 42 · see citing works
Liposomal Aerosols in the Management of Pulmonary Infections
Gilbert, B. E. (1996) · Journal of Aerosol Medicine · doi:10.1089/jam.1996.9.111 · Cited by 38 · see citing works
Chamilos, G., Luna, M. A., Lewis, R. E., Chemaly, R. F., RAAD, I. I., & Kontoyiannis, D. P. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.016 · Cited by 38 · see citing works
Liposomal amphotericin B therapy of murine histoplasmosis
Graybill, J. R., & Bocanegra, R. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.8.1885 · Cited by 37 · see citing works
Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B
Strenger, V., Meinitzer, A., Donnerer, J., Hofer, N., Dornbusch, H. J., Wanz, U., Seidel, M. G., Sperl, D., Lackner, H., Schwinger, W., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku148 · Cited by 36 · see citing works
Al-Nakeeb, Z., Petraitis, V., Goodwin, J., Petraitienė, R., Walsh, T. J., & Hope, W. W. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04723-14 · Cited by 34 · see citing works
Self-citationEvaluation of Antifungal Pharmacodynamic Characteristics of AmBisome against Candida albicans
Takemoto, K., Yamamoto, Y., & Ueda, Y. (2006) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2006.tb03832.x · Cited by 33 · see citing works
Shimizu, K., Osada, M., Takemoto, K., Yamamoto, Y., Asai, T., & Oku, N. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.019 · Cited by 33 · see citing works
Clemons, K. V., Schwartz, J. A., & Stevens, D. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06015-11 · Cited by 32 · see citing works
Low‐dose amphotericin for prevention of serious fungal infection following liver transplantation
Shah, T., Lai, W. K., Gow, P. J., Leeming, J., & Mutimer, D. (2005) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2005.00108.x · Cited by 32 · see citing works
Hope, W. W., Goodwin, J., Felton, T., Ellis, M. E., & Stevens, D. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00933-12 · Cited by 32 · see citing works
Self-citationKirkpatrick, W. R., Coco, B. J., & Patterson, T. F. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1567-1569.2006 · Cited by 31 · see citing works
Uhlenbrock, S., Zimmermann, M., Fegeler, W., Jürgens, H., & Ritter, J. (2001) · Mycoses · doi:10.1046/j.1439-0507.2001.00706.x · Cited by 31 · see citing works
Olson, J. A., George, A., Constable, D., Smith, P., Proffitt, R. T., & Adler‐Moore, J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01554-09 · Cited by 30 · see citing works
Pharmacokinetics of Liposomal Amphotericin B in Pleural Fluid
Moriyama, B., Torabi‐Parizi, P., Pratt, A. K., Henning, S. A., Pennick, G. J., M.S., Y. R. S., Roy‐Chowdhuri, S., Rinaldi, M. G., Barrett, A. J., & Walsh, T. J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01438-09 · Cited by 25 · see citing works
Lanternier, F., & Lortholary, O. (2008) · Médecine et Maladies Infectieuses · doi:10.1016/s0399-077x(08)73003-8 · Cited by 24 · see citing works
Lewis, R. E., Albert, N. D., & Kontoyiannis, D. P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00715-08 · Cited by 23 · see citing works
Differences in Pharmacokinetics of Amphotericin B Lipid Formulations Despite Clinical Equivalence
Bellmann, R., Egger, P., & Wiedermann, C. J. (2003) · Clinical Infectious Diseases · doi:10.1086/374876 · Cited by 22 · see citing works
Kamalaporn, H., Leung, K., NAGEL, M. W., Kittanakom, S., Calvieri, B., Reithmeier, R. A. F., & Coates, A. L. (2013) · Pediatric Pulmonology · doi:10.1002/ppul.22856 · Cited by 15 · see citing works
Efficacy of AmBisome in murine coccidioidomycosis
Albert, M. M., Adams, K., Luther, M., Sun, S. H., & Graybill, J. R. (1994) · Medical Mycology · doi:10.1080/02681219480000621 · Cited by 14 · see citing works
Amphotericin B Dose Optimization in Children with Malignant Diseases
Nath, C. E., McLachlan, A. J., Shaw, P. J., Coakley, J. C., & Earl, J. W. (2007) · Chemotherapy · doi:10.1159/000100013 · Cited by 13 · see citing works
Krñger, W., Stockschläder, M., Sobottka, I., Betker, R., de Wit, M., Kröger, N. M., Grimm, J., Arland, M., Fiedler, W., Erttmann, R., et al. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709055586 · Cited by 12 · see citing works
Cornely, O. A., Leguay, T., Maertens, J. A., Castagnola, C., Anagnostopoulos, Α., Allione, B., Heußel, C. P., Donnelly, J. P., Agrawal, S. G., Garner, W., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3646.3646 · Cited by 10 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [94]Lanternier F Lortholary O [AMBIZYGO: phase II study of high dose liposomal amphotericin B (AmBisome) [10 mg/kg/j] efficacy against zygomycosis] Med Mal Infect 2008 6 38 Suppl 2 S90 1 18598882
Cited by
Sorted by citations
Aspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400 · see citing works
Mehta, M., Bui, T. A., Yang, X., Aksoy, Y. A., Goldys, E. M., & Deng, W. (2023) · ACS Materials Au · doi:10.1021/acsmaterialsau.3c00032 · Cited by 740 · see citing works
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0120 · Cited by 664 · see citing works
Recent advancements in liposome technology
Filipczak, N., Pan, J., Yalamarty, S. S. K., & Torchilin, V. P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.022 · Cited by 604 · see citing works
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 546 · see citing works
Biocompatibility of nanomaterials and their immunological properties
Kyriakides, T. R., Raj, A., Tseng, T. H., Xiao, H., Nguyen, R. Y., Mohammed, F. S., Halder, S. S., Xu, M., Wu, M. J., Bao, S., et al. (2021) · Biomedical Materials · doi:10.1088/1748-605x/abe5fa · Cited by 407 · see citing works
Cavassin, F. B., Baú-Carneiro, J. L., Boas, R. R. V., & Queiroz‐Telles, F. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00382-7 · Cited by 390 · see citing works
Treatment strategies for cryptococcal infection: challenges, advances and future outlook
Iyer, K. R., Revie, N. M., Fu, C., Robbins, N., & Cowen, L. E. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00511-0 · Cited by 363 · see citing works
Leishmaniasis in humans: drug or vaccine therapy?
Ghorbani, M., & Farhoudi, R. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s146521 · Cited by 356 · see citing works
Amphotericin B and Other Polyenes—Discovery, Clinical Use, Mode of Action and Drug Resistance
Carolus, H., Pierson, S., Lagrou, K., & Dijck, P. V. (2020) · Journal of Fungi · doi:10.3390/jof6040321 · Cited by 364 · see citing works
Candida parapsilosis: from genes to the bedside
Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., Turner, S. A., Butler, G., Vágvölgyi, C., & Gácser, A. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00111-18 · Cited by 327 · see citing works
Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., & Vora, L. K. (2025) · Small · doi:10.1002/smll.202502315 · Cited by 323 · see citing works
Why nanoparticles prefer liver macrophage cell uptake in vivo
Ngo, W., Ahmed, S., Blackadar, C., Bussin, B., Ji, Q. C., Mladjenovic, S. M., Sepahi, Z., & Chan, W. C. W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114238 · Cited by 261 · see citing works
Phytochemical delivery through nanocarriers: a review
Ahmad, R., Srivastava, S., Ghosh, S., & Khare, S. K. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.111389 · Cited by 216 · see citing works
Nanocarriers for the Delivery of Medical, Veterinary, and Agricultural Active Ingredients
Chariou, P. L., Ortega-Rivera, O. A., & Steinmetz, N. F. (2020) · ACS Nano · doi:10.1021/acsnano.0c00173 · Cited by 212 · see citing works
Solubilization techniques used for poorly water-soluble drugs
Xie, B., Liu, Y., Li, X., Yang, P., & He, W. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.08.027 · Cited by 230 · see citing works
Cryptococcus neoformans, a global threat to human health
Zhao, Y., Ye, L., Zhao, F., Zhang, L., Lu, Z., Chu, T., Wang, S., Liu, Z., Sun, Y., Chen, M., et al. (2023) · Infectious Diseases of Poverty · doi:10.1186/s40249-023-01073-4 · Cited by 206 · see citing works
Safe nanomaterials: from their use, application, and disposal to regulations
Chávez-Hernández, J. A., Velarde‐Salcedo, A. J., Navarro‐Tovar, G., & González, C. (2024) · Nanoscale Advances · doi:10.1039/d3na01097j · Cited by 198 · see citing works
Targeting of Hepatic Macrophages by Therapeutic Nanoparticles
Colino, C. I., Lanao, J. M., & Millán, C. G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00218 · Cited by 186 · see citing works
Liposome-based delivery of biological drugs
Magar, K. T., Boafo, G. F., Li, X., Chen, Z., & He, W. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.08.020 · Cited by 185 · see citing works
Walker, L. A., Sood, P., Lenardon, M. D., Milne, G., Olson, J. A., Jensen, G. M., Wolf, J. M., Casadevall, A., Adler‐Moore, J., & Gow, N. A. R. (2018) · mBio · doi:10.1128/mbio.02383-17 · Cited by 170 · see citing works
Man, F., Gawne, P. J., & de Rosales, R. T. M. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.012 · Cited by 163 · see citing works
Approved Nanomedicine against Diseases
Jia, Y., Jiang, Y., He, Y., Zhang, W., Zou, J., Magar, K. T., Boucetta, H., Teng, C., & He, W. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030774 · Cited by 169 · see citing works
Emerging Antifungal Targets and Strategies
Ivanov, M., Ćirić, A., & Stojković, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052756 · Cited by 160 · see citing works
Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 160 · see citing works
Jenks, J. D., & Hoenigl, M. (2018) · Journal of Fungi · doi:10.3390/jof4030098 · Cited by 141 · see citing works
The Impact of Nanoparticles on the Immune System: A Gray Zone of Nanomedicine
Ray, P., Haideri, N., Haque, I., Mohammed, O. F., Chakraborty, S., Banerjee, S., Quadir, M., Brinker, A. E., & Banerjee, S. K. (2021) · Journal of Immunological Sciences · doi:10.29245/2578-3009/2021/1.1206 · Cited by 140 · see citing works
Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B
Groll, A. H., Rijnders, B. J. A., Walsh, T. J., Adler‐Moore, J., Lewis, R. E., & Brüggemann, R. J. M. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz076 · Cited by 135 · see citing works
Emerging New Targets for the Treatment of Resistant Fungal Infections
Liu, N., Tu, J., Dong, G., Wang, Y., & Sheng, C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01413 · Cited by 129 · see citing works
Microfluidic Manufacture of Lipid-Based Nanomedicines
Osouli-Bostanabad, K., Puliga, S., Serrano, D. R., Bucchi, A., Halbert, G., & Lalatsa, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091940 · Cited by 130 · see citing works
Understanding nanoparticle-liver interactions in nanomedicine
He, Y., Wang, Y., Wang, L., Jiang, W., & Wilhelm, S. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2375400 · Cited by 140 · see citing works
Tugume, L., Ssebambulidde, K., Kasibante, J., Ellis, J. P., Wake, R. M., Gakuru, J., Lawrence, D. S., Abassi, M., Rajasingham, R., Meya, D. B., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00472-z · Cited by 125 · see citing works
Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies
Wei, Q.-Y., Xu, Y., & Lau, A. T. Y. (2020) · Cancers · doi:10.3390/cancers12102783 · Cited by 121 · see citing works
Wang, Z., Wang, X.-P., Xu, W., Li, Y.-X., Lai, R.-Z., Qiu, X.-H., Chen, X., Chen, Z.-D., Mi, B., Wu, M., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112623 · Cited by 102 · see citing works
Antifungals and Drug Resistance
Hossain, C. M., Ryan, L. K., Gera, M., Choudhuri, S., Lyle, N., Ali, K. A., & Diamond, G. (2022) · Encyclopedia · doi:10.3390/encyclopedia2040118 · Cited by 127 · see citing works
Stott, K. E., & Hope, W. W. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx029 · Cited by 115 · see citing works
Self-citationRegulating nanomedicines: challenges, opportunities, and the path forward
Mangla, B., Kumar, P., Javed, S., Pathan, T., Ahsan, W., & Aggarwal, G. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2533107 · Cited by 123 · see citing works
Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions
Anchordoquy, T. J., Artzi, N., Balyasnikova, I. V., Barenholz, Y., La-Beck, N. M., Brenner, J. S., Chan, W. C. W., Decuzzi, P., Exner, A. A., Gabizón, A., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c00182 · Cited by 111 · see citing works
Mucormycosis in Children: Review and Recommendations for Management
Francis, J. R., Villanueva, P., Bryant, P. A., & Blyth, C. C. (2017) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/pix107 · Cited by 109 · see citing works
Liposome bilayer stability: emphasis on cholesterol and its alternatives
Nsairat, H., Ibrahim, A. A., Jaber, A. M., Abdelghany, S. M., Atwan, R., Shalan, N. M., Abdelnabi, H., Odeh, F., El‐Tanani, M., & Alshaer, W. (2023) · Journal of Liposome Research · doi:10.1080/08982104.2023.2226216 · Cited by 109 · see citing works
Nanotools for Sepsis Diagnosis and Treatment
Papafilippou, L., Claxton, A., Dark, P., Kostarelos, K., & Hadjidemetriou, M. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001378 · Cited by 118 · see citing works
Small-molecule ion channels increase host defences in cystic fibrosis airway epithelia
Muraglia, K. A., Chorghade, R. S., Kim, B. R., Tang, X. X., Shah, V. S., Grillo, A. S., Daniels, P. N., Cioffi, A. G., Karp, P. H., Zhu, L., et al. (2019) · Nature · doi:10.1038/s41586-019-1018-5 · Cited by 107 · see citing works
John, J., Loo, A. S., Mazur, S., & Walsh, T. J. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1671971 · Cited by 107 · see citing works
Altamura, F., Rajesh, R., Catta‐Preta, C. M. C., Moretti, N. S., & Cestari, I. D. S. (2020) · Drug Development Research · doi:10.1002/ddr.21664 · Cited by 101 · see citing works
Nano-based drug delivery system for therapeutics: a comprehensive review
Prakash, S. (2023) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/acedb2 · Cited by 101 · see citing works
Approved and marketed nanoparticles for disease targeting and applications in COVID-19
Abdellatif, A. A. H., & Alsowinea, A. F. (2021) · Nanotechnology Reviews · doi:10.1515/ntrev-2021-0115 · Cited by 101 · see citing works
The impact of obesity on immune response to infection: Plausible mechanisms and outcomes
Muscogiuri, G., Pugliese, G., Laudisio, D., Castellucci, B., Barrea, L., Savastano, S., & Colao, A. (2021) · Obesity Reviews · doi:10.1111/obr.13216 · Cited by 94 · see citing works
Lipid-Based Nanotechnology: Liposome
Jiang, Y., Li, W., Wang, Z., & Lu, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010034 · Cited by 94 · see citing works
Amphotericin B: A drug of choice for Visceral Leishmaniasis
Kumari, S., Kumar, V., Tiwari, R. K., Ravidas, V., Pandey, K., & Kumar, A. (2022) · Acta Tropica · doi:10.1016/j.actatropica.2022.106661 · Cited by 90 · see citing works
Topical delivery of pharmaceutical and cosmetic macromolecules using microemulsion systems
Szumała, P., & Macierzanka, A. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121488 · Cited by 91 · see citing works
Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs
Kip, A. E., Schellens, J. H. M., Beijnen, J. H., & Dorlo, T. P. C. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0570-0 · Cited by 84 · see citing works
Adler‐Moore, J., Lewis, R. E., Brüggemann, R. J. M., Rijnders, B. J. A., Groll, A. H., & Walsh, T. J. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz064 · Cited by 85 · see citing works
Carbon Dots as Drug Delivery Vehicles for Antimicrobial Applications: A Minireview
Wang, Z., Wang, Z., & Wu, F. (2022) · ChemMedChem · doi:10.1002/cmdc.202200003 · Cited by 83 · see citing works
Biofilms and Chronic Wounds: Pathogenesis and Treatment Options
Shen, A., Taha, M. R., Ghannoum, M. A., & Tyring, S. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217784 · Cited by 92 · see citing works
Efficacy and safety of amphotericin B lipid‐based formulations—A systematic review and meta‐analysis
Steimbach, L. M., Tonin, F. S., Virtuoso, S., Borba, H. H. L., Sanches, A. C. C., Wiens, A., Fernández-Llimós, F., & Pontarolo, R. (2016) · Mycoses · doi:10.1111/myc.12585 · Cited by 81 · see citing works
He, H., Yuan, D., Wu, Y., & Cao, Y. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11030110 · Cited by 80 · see citing works
Engineering Tumor-Targeting Nanoparticles as Vehicles for Precision Nanomedicine
Gonda, A., Zhao, N., Shah, J. V., Calvelli, H. R., Kantamneni, H., Francis, N. L., & Ganapathy, V. (2019) · Med One · doi:10.20900/mo.20190021 · Cited by 80 · see citing works
Antileishmanial Drug Discovery and Development: Time to Reset the Model?
Olías-Molero, A. I., de la Fuente, C., Cuquerella, M., Torrado, J. J., & Alunda, J. M. (2021) · Microorganisms · doi:10.3390/microorganisms9122500 · Cited by 80 · see citing works
Pharmaceutical liposomal delivery—specific considerations of innovation and challenges
Peng, T., Xu, W., Li, Q., Ding, Y., & Huang, Y. (2022) · Biomaterials Science · doi:10.1039/d2bm01252a · Cited by 80 · see citing works
Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight
Jamshaid, H., Din, F. U., & Khan, G. M. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00853-0 · Cited by 72 · see citing works
Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea
Guéry, R., Henry, B., Martin‐Blondel, G., Rouzaud, C., Cordoliani, F., Harms, G., Gangneux, J., Foulet, F., Bourrat, E., Baccard, M., et al. (2017) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0006094 · Cited by 71 · see citing works
Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis
Ammar, A. A., Nasereddin, A., Ereqat, S., Dan‐Goor, M., Jaffe, C. L., Zussman, E., & Abdeen, Z. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-00603-0 · Cited by 70 · see citing works
Multivesicular Vesicles: Preparation and Applications
Giuliano, C. B., Cvjetan, N., Ayache, J., & Walde, P. (2020) · ChemSystemsChem · doi:10.1002/syst.202000049 · Cited by 67 · see citing works
Cuddihy, G., Wasan, E. K., Di, Y., & Wasan, K. M. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11030099 · Cited by 67 · see citing works
Ionic Liquids in Drug Delivery
Pedro, S. N., Freire, C. S. R., Silvestre, A. J. D., & Freire, M. G. (2021) · Encyclopedia · doi:10.3390/encyclopedia1020027 · Cited by 68 · see citing works
Protein corona fingerprinting to differentiate sepsis from non-infectious systemic inflammation
Papafilippou, L., Claxton, A., Dark, P. M., Kostarelos, K., & Hadjidemetriou, M. (2020) · Nanoscale · doi:10.1039/d0nr02788j · Cited by 65 · see citing works
Nanoparticles for drug delivery in Parkinson’s disease
Baskin, J., Jeon, J. E., & Lewis, S. J. G. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10291-x · Cited by 65 · see citing works
Prasanna, P., Kumar, P., Kumar, S., Rajana, V. K., Kant, V., Prasad, S. R., Mohan, U., Ravichandiran, V., & Mandal, D. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111920 · Cited by 67 · see citing works
Francesco, M. A. D. (2023) · Pathogens · doi:10.3390/pathogens12111305 · Cited by 65 · see citing works
Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases
Lanza, J. S., Pomel, S., Loiseau, P. M., & Frézard, F. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1659243 · Cited by 62 · see citing works
Transmembrane Ion Channels: From Natural to Artificial Systems
Yan, T., & Liu, J. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202416200 · Cited by 62 · see citing works
Dectin-1-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy
Ambati, S., Ferraro, A. R., Kang, S., Lin, J., Lin, X., Momany, M., Lewis, Z., & Meagher, R. B. (2019) · mSphere · doi:10.1128/msphere.00025-19 · Cited by 59 · see citing works
Lysosomal nanotoxicity: Impact of nanomedicines on lysosomal function
Uzhytchak, M., Smolková, B., Lunová, M., Frtús, A., Jirsa, M., Dejneka, A., & Lunov, O. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114828 · Cited by 60 · see citing works
Advances in Biomaterials for the Prevention and Disruption of Candida Biofilms
Vera‐González, N., & Shukla, A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.538602 · Cited by 59 · see citing works
Haro-Reyes, T., Díaz-Peralta, L., Galván‐Hernández, A., Rodríguez‐López, A., Rodríguez‐Fragoso, L., & Ortega‐Blake, I. (2022) · Membranes · doi:10.3390/membranes12070681 · Cited by 56 · see citing works
Immune Implications of Cholesterol-Containing Lipid Nanoparticles
Back, P. I., Yu, M., Modaresahmadi, S., Hajimirzaei, S., Zhang, Q., Islam, M. R., Schwendeman, A. A., & La-Beck, N. M. (2024) · ACS Nano · doi:10.1021/acsnano.4c06369 · Cited by 56 · see citing works
Emerging nanotechnologies for targeting antimicrobial resistance
Weldrick, P. J., Wang, A., Halbus, A. F., & Paunov, V. N. (2022) · Nanoscale · doi:10.1039/d1nr08157h · Cited by 55 · see citing works
Current and promising novel drug candidates against visceral leishmaniasis
Reguera, R. M., Pérez‐Pertejo, Y., Gutiérrez-Corbo, C., Domínguez-Asenjo, B., Ordóñez, C., García‐Estrada, C., Valladares, M. M., & Balaña‐Fouce, R. (2019) · Pure and Applied Chemistry · doi:10.1515/pac-2018-1102 · Cited by 56 · see citing works
Screening Marine Natural Products for New Drug Leads against Trypanosomatids and Malaria
Álvarez-Bardón, M., Pérez‐Pertejo, Y., Ordóñez, C., Sepúlveda‐Crespo, D., Carballeira, N. M., Tekwani, B. L., Murugesan, S., Valladares, M. M., García‐Estrada, C., Reguera, R. M., et al. (2020) · Marine Drugs · doi:10.3390/md18040187 · Cited by 57 · see citing works
Nano-formulations in disease therapy: designs, advances, challenges, and future directions
Shi, Y., Li, X., Li, Z., Sun, J., Gao, T., Wei, G., & Guo, Q. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03442-7 · Cited by 56 · see citing works
Li, J., Tan, T., Zhao, L., Liu, M., You, Y., Zeng, Y., Chen, D., Xie, T., Zhang, L., Fu, C., et al. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00705 · Cited by 50 · see citing works
Lipid and fatty acid metabolism in trypanosomatids
de Aquino, G. P., Gomes, M. A. M., Salinas, R. K., & Laranjeira‐Silva, M. F. (2021) · Microbial Cell · doi:10.15698/mic2021.11.764 · Cited by 50 · see citing works
Shirzadi, M. R. (2019) · Research and Reports in Tropical Medicine · doi:10.2147/rrtm.s200218 · Cited by 49 · see citing works
Vera‐González, N., Bailey‐Hytholt, C. M., Langlois, L., Ribeiro, F. D. C., Santos, E. L. D. S., Junqueira, J. C., & Shukla, A. (2020) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36984 · Cited by 49 · see citing works
Antifungal therapy: Novel drug delivery strategies driven by new targets
Wu, S., Song, R., Liu, T., & Li, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114967 · Cited by 48 · see citing works
Nanotechnology in the Diagnosis and Treatment of Antibiotic-Resistant Infections
Ιωάννου, Π., Baliou, S., & Samonis, G. (2024) · Antibiotics · doi:10.3390/antibiotics13020121 · Cited by 49 · see citing works
Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications
Dhayalan, M., Wang, W., Riyaz, S. U. M., Dinesh, R. A., Shanmugam, J., Irudayaraj, S. S., Stalin, A., Giri, J. P., Mallik, S., & Hu, R. (2024) · 3 Biotech · doi:10.1007/s13205-023-03901-8 · Cited by 48 · see citing works
Prevention of paclitaxel-induced neuropathy by formulation approach
Zang, X., Lee, J. B., Deshpande, K., Garbuzenko, O. B., Minko, T., & Kagan, L. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.013 · Cited by 47 · see citing works
Recent drug development and treatments for fungal infections
Roy, M., Karhana, S., Shamsuzzaman, M., & Khan, M. A. (2023) · Brazilian Journal of Microbiology · doi:10.1007/s42770-023-00999-z · Cited by 45 · see citing works
Molecular Mechanisms of Drug Resistance in Leishmania spp.
Moncada-Díaz, M. J., Rodríguez-Almonacid, C. C., Quiceno, E., Khuong, F. T. H., Muskus, C., & Karamysheva, Z. N. (2024) · Pathogens · doi:10.3390/pathogens13100835 · Cited by 47 · see citing works
Dectin-2-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy
Ambati, S., Ellis, E. C., Lin, J., Lin, X., Lewis, Z., & Meagher, R. B. (2019) · mSphere · doi:10.1128/msphere.00715-19 · Cited by 51 · see citing works
Pre-Existing Liver Disease and Toxicity of Antifungals
Spernovasilis, N. A., & Kofteridis, D. P. (2018) · Journal of Fungi · doi:10.3390/jof4040133 · Cited by 44 · see citing works
Zakaria, A., Osman, M., Dabboussi, F., Rafei, R., Mallat, H., Papon, N., Bouchara, J., & Hamzé, M. (2019) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2019.08.007 · Cited by 44 · see citing works
Jafari, M., Abolmaali, S. S., Tamaddon, A. M., Zomorodian, K., & Sarkari, B. (2021) · Nanomedicine · doi:10.2217/nnm-2020-0482 · Cited by 44 · see citing works
Polyphenols against infectious diseases: Controlled release nano-formulations
Murthy, N. T. V., Agrahari, V., & Chauhan, H. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.02.003 · Cited by 43 · see citing works
Advancing Medicine with Lipid-Based Nanosystems—The Successful Case of Liposomes
Luiz, H., Pinho, J. O., & Gaspar, M. M. (2023) · Biomedicines · doi:10.3390/biomedicines11020435 · Cited by 43 · see citing works
Overview of antifungal dosing in invasive candidiasis
Pea, F., & Lewis, R. E. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx447 · Cited by 42 · see citing works
Matsuura-Sawada, Y., Maeki, M., Uno, S., Wada, K., & Tokeshi, M. (2023) · Biomaterials Science · doi:10.1039/d2bm01703b · Cited by 41 · see citing works
Targeting and synergistic action of an antifungal peptide in an antibiotic drug-delivery system
Park, S., Kim, Y., Lee, J., Kim, N.-H., Kim, E.-J., Heo, H., Lee, M. Y., Lee, J. R., & Jang, M.-K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.023 · Cited by 41 · see citing works
Review of methods and antimicrobial agents for susceptibility testing against Pythium insidiosum
Yolanda, H., & Krajaejun, T. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03737 · Cited by 41 · see citing works
- Authors
- Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W.
- Affiliations
- St George's, University of London (GB)
- Royal Liverpool University Hospital (GB)
- University of Liverpool (GB)
- Corresponding author
- Stone, Neil R. H.
- Venue
- Drugs
- Published
- 2016-01-27
- Volume
- 76
- Issue
- 4
- Pages
- 485-500
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC4856207
- OpenAlex
- W2298912458
- Cited by
- 537
- References
- 119
- Citations by year
- 2026: 52 · 2025: 81 · 2024: 73 · 2023: 61 · 2022: 73 · 2021: 60 · 2020: 55 · 2019: 40 · 2018: 16 · 2017: 23 · 2016: 1
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust Strategic Award (Medical Mycology and Fungal Immunology) (RG12848-10)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Health Sciences › Medicine › Pharmacology › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- liposomal amphotericin B, amphotericin B deoxycholate, pharmacokinetics, pharmacodynamics, antifungal agents, opportunistic fungal infection, drug toxicity, dosing regimen, intermittent dosing, neonates, pregnancy, obesity, molecular pharmacology
- MeSH terms
- Amphotericin B, Animals, Chemistry, Pharmaceutical, Clinical Trials as Topic, Deoxycholic Acid, Drug Combinations, Half-Life, Humans, Tissue Distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
